Search - tctmd.com

Displaying 1 - 20 of 180

Sort: Relevancy | Date

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

News Opinion CV Team Dispatch

March 2026 Dispatch for the CV Team

L.A. McKeown

March 26, 2026

News Daily News

No Major Progress on Making CV Care More Affordable: JACC Stats

Todd Neale

March 18, 2026

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

News Daily News

Ataciguat Shows Potential for Curbing Progression of Aortic Stenosis

Yael L. Maxwell

February 27, 2025

News Daily News

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

Michael O'Riordan

February 24, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Michael O'Riordan

January 03, 2025

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Conference News ESOC 2024

Colchicine Misses in Secondary Stroke Prevention, but Door Not Closed Yet

Todd Neale

May 16, 2024

News Opinion CV Team Dispatch

May 2024 Dispatch for the CV Team

L.A. McKeown

May 01, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Opinion CV Team Dispatch

April 2024 Dispatch for the CV Team

L.A. McKeown

April 01, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

Advertisement

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

March 2026 Dispatch for the CV Team

No Major Progress on Making CV Care More Affordable: JACC Stats

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Ataciguat Shows Potential for Curbing Progression of Aortic Stenosis

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

November 2024 Dispatch for the CV Team

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Colchicine Misses in Secondary Stroke Prevention, but Door Not Closed Yet

May 2024 Dispatch for the CV Team

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

April 2024 Dispatch for the CV Team

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content